CRISPR Therapeutics AG — Director's Dealing 2017

Jun 19, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-06-15

Reporting Person: Subramanian Kala (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-15	Stock Options (Right to Buy)	$14.43	A	85000	Acquired	2027-06-15	Common Shares (85000)	Direct

Footnotes

F1: This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.